Profile data is unavailable for this security.
About the company
Charles River Laboratories International, Inc. provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. The Company's Research Models and Services segment is comprised of three businesses that provide foundational tools that enables its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.
- Revenue in USD (TTM)4.13bn
- Net income in USD474.62m
- Incorporated1994
- Employees20.00k
- LocationCharles River Laboratories International Inc251 Ballardvale StWILMINGTON 01887United StatesUSA
- Phone+1 (781) 222-6000
- Fax+1 (978) 988-5665
- Websitehttps://www.criver.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
KBR Inc | 6.96bn | -265.00m | 8.78bn | 34.00k | -- | 6.37 | -- | 1.26 | -2.03 | -2.03 | 50.04 | 10.24 | 1.25 | -- | 5.91 | 204,588.20 | -4.69 | 0.4725 | -6.77 | 0.6678 | 14.05 | 12.18 | -3.75 | 0.4122 | -- | 1.14 | 0.5679 | 340.00 | 5.97 | 7.20 | -240.21 | -- | 36.31 | 11.03 |
Repligen Corp | 638.76m | 41.58m | 9.25bn | 1.78k | 229.85 | 4.69 | 84.35 | 14.48 | 0.7207 | 0.7207 | 11.27 | 35.35 | 0.2388 | 1.47 | 5.31 | 358,252.40 | 1.55 | 4.38 | 1.74 | 5.03 | 49.35 | 55.43 | 6.51 | 15.91 | 5.75 | -- | 0.2272 | 0.00 | -20.31 | 26.91 | -77.64 | 20.13 | 24.99 | -- |
BIO-TECHNE Corp | 1.14bn | 224.12m | 9.85bn | 3.05k | 45.20 | 5.01 | 29.45 | 8.60 | 1.39 | 1.39 | 7.09 | 12.50 | 0.4495 | 2.21 | 5.84 | 375,409.50 | 8.80 | 9.57 | 9.28 | 10.20 | 67.13 | 67.35 | 19.58 | 21.91 | 3.03 | 18.86 | 0.1854 | 24.19 | 2.81 | 12.07 | 4.88 | 25.13 | 12.81 | 0.00 |
Catalent Inc | 4.10bn | -1.30bn | 10.10bn | 17.80k | -- | 2.74 | -- | 2.46 | -7.18 | -7.18 | 22.52 | 20.37 | 0.3878 | 4.09 | 3.00 | 230,224.70 | -12.32 | 2.88 | -14.02 | 3.26 | 17.94 | 31.03 | -31.77 | 6.35 | 1.71 | -0.625 | 0.5758 | 0.00 | -11.22 | 11.59 | -153.00 | -- | 26.69 | -- |
Exact Sciences Corp | 2.50bn | -204.15m | 10.67bn | 6.50k | -- | 3.39 | 4,340.06 | 4.27 | -1.14 | -1.14 | 13.81 | 17.34 | 0.3937 | 5.32 | 13.82 | 384,579.40 | -3.22 | -9.71 | -3.47 | -10.60 | 73.83 | 74.10 | -8.17 | -28.21 | 2.07 | -- | 0.4311 | -- | 19.93 | 40.63 | 67.26 | -- | -3.71 | -- |
United Therapeutics Corporation | 2.33bn | 984.80m | 11.10bn | 1.17k | 11.90 | 1.85 | 10.70 | 4.77 | 19.82 | 19.82 | 46.83 | 127.23 | 0.3523 | 2.41 | 9.32 | 1,992,723.00 | 14.91 | 10.38 | 16.33 | 11.27 | 88.94 | 91.47 | 42.31 | 29.25 | 4.28 | -- | 0.1047 | 0.00 | 20.20 | 7.41 | 35.40 | 10.89 | 4.55 | -- |
Natera Inc | 1.08bn | -434.80m | 11.16bn | 3.28k | -- | 14.26 | -- | 10.31 | -3.80 | -3.80 | 9.41 | 6.40 | 0.7634 | 15.49 | 4.14 | 329,851.00 | -30.66 | -36.17 | -39.20 | -46.60 | 45.52 | 45.88 | -40.16 | -56.15 | 3.96 | -- | 0.3219 | -- | 31.99 | 33.26 | 20.63 | -- | 58.81 | -- |
Incyte Corp | 3.70bn | 597.60m | 11.49bn | 2.52k | 19.36 | 2.21 | 16.89 | 3.11 | 2.64 | 2.64 | 16.36 | 23.14 | 0.5855 | 4.43 | 5.32 | 1,464,203.00 | 9.47 | 9.07 | 11.69 | 11.02 | 93.71 | 94.97 | 16.17 | 13.68 | 3.69 | -- | 0.0062 | 0.00 | 8.87 | 14.45 | 75.42 | 40.41 | -15.06 | -- |
Charles River Lbrtrs ntrntl Inc | 4.13bn | 474.62m | 11.73bn | 20.00k | 24.68 | 3.25 | 14.77 | 2.84 | 9.23 | 9.23 | 80.25 | 70.06 | 0.5228 | 8.19 | 5.39 | 206,470.50 | 6.08 | 6.46 | 7.09 | 7.62 | 36.89 | 36.99 | 11.63 | 11.58 | 1.16 | 4.97 | 0.4203 | 0.00 | 3.86 | 12.75 | -2.39 | 16.69 | 17.86 | -- |
Sarepta Therapeutics Inc | 1.24bn | -535.98m | 11.96bn | 1.31k | -- | 13.90 | -- | 9.62 | -6.15 | -6.15 | 13.46 | 9.17 | 0.389 | 0.5708 | 4.04 | 946,222.30 | -16.77 | -21.63 | -20.94 | -25.75 | 87.91 | 86.65 | -43.11 | -77.05 | 3.45 | -- | 0.5903 | -- | 33.26 | 32.80 | 23.81 | -- | 6.30 | -- |
Medpace Holdings Inc | 1.96bn | 312.32m | 12.08bn | 5.80k | 39.72 | 17.94 | 35.53 | 6.15 | 9.81 | 9.81 | 61.73 | 21.72 | 1.23 | -- | 7.31 | 332,680.00 | 19.58 | 13.94 | 46.20 | 23.18 | 27.99 | 28.84 | 15.92 | 15.23 | -- | -- | 0.00 | -- | 29.17 | 21.76 | 15.26 | 31.17 | 17.99 | -- |
Viatris Inc | 15.43bn | 54.70m | 13.62bn | 38.00k | 270.97 | 0.6729 | 4.87 | 0.883 | 0.0423 | 0.0423 | 12.81 | 17.05 | 0.3158 | 2.49 | 5.09 | 405,971.10 | 0.112 | 0.0887 | 0.1315 | 0.1061 | 43.64 | 40.29 | 0.3546 | 0.2891 | 1.22 | 2.79 | 0.4696 | 560.11 | -5.14 | 6.17 | -97.37 | -30.53 | -16.88 | -- |
Neurocrine Biosciences, Inc. | 1.89bn | 249.70m | 13.86bn | 1.40k | 56.66 | 6.09 | 51.13 | 7.34 | 2.43 | 2.43 | 18.84 | 22.61 | 0.6716 | 1.08 | 4.78 | 1,347,929.00 | 8.89 | 9.77 | 11.28 | 12.19 | 97.90 | 98.51 | 13.23 | 14.79 | 2.40 | -- | 0.0708 | -- | 26.76 | 33.13 | 61.62 | 63.90 | 2.67 | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 31 Dec 2023 | 5.77m | 11.23% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 3.05m | 5.94% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 2.06m | 4.01% |
Kayne Anderson Rudnick Investment Management LLCas of 31 Dec 2023 | 1.75m | 3.41% |
ClearBridge Investments LLCas of 31 Dec 2023 | 1.47m | 2.86% |
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 2023 | 1.37m | 2.68% |
Meritage Group LPas of 31 Dec 2023 | 1.16m | 2.25% |
Geode Capital Management LLCas of 31 Dec 2023 | 1.15m | 2.23% |
BlackRock Advisors LLCas of 31 Dec 2023 | 1.13m | 2.20% |
Allspring Global Investments LLCas of 31 Mar 2024 | 1.11m | 2.16% |